Twist Bioscience Corporation (ETR:0ME)
| Market Cap | 6.42B +375.6% |
| Revenue (ttm) | 404.58M +22.0% |
| Net Income | -114.66M |
| EPS | -1.90 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11 |
| Open | 98.92 |
| Previous Close | 110.80 |
| Day's Range | 95.16 - 98.92 |
| 52-Week Range | 92.62 - 159.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Twist Bioscience
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library prep... [Read more]
Financial Performance
In fiscal year 2026, Twist Bioscience's revenue was $459.43 million, an increase of 22.00% compared to the previous year's $376.57 million. Losses were -$130.20 million, 67.6% more than in 2025.
Financial numbers in USD Financial StatementsNews
Twist Bioscience Transcript: Jefferies Global Healthcare Conference
Silicon-chip DNA synthesis supports a $7B 2026 serviceable market, with line of sight to $13B. AI drug-discovery revenue reached $59M in 2026 and is guided to at least $100M in 2027, with capacity the key constraint.
Twist Bioscience price target lowered to $130 from $215 at Barclays
Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $130 from $215 and keeps an Overweight rating on the shares after speaking with management. The firm says Twist’s…
Twist Bioscience price target lowered to $120 from $190 at UBS
UBS lowered the firm’s price target on Twist Bioscience (TWST) to $120 from $190 and keeps a Neutral rating on the shares. The company’s fiscal Q4 slightly exceeded expectations and…
Twist Bioscience price target lowered to $175 from $190 at Leerink
Leerink analyst Puneet Souda lowered the firm’s price target on Twist Bioscience (TWST) to $175 from $190 and keeps an Outperform rating on the shares. The firm continues to believe…
Twist Bioscience price target lowered to $137 from $190 at TD Cowen
TD Cowen lowered the firm’s price target on Twist Bioscience (TWST) to $137 from $190 and keeps a Buy rating on the shares. The firm noted the company emphasized initial…
Twist Bioscience price target lowered to $135 from $187 at Baird
Baird lowered the firm’s price target on Twist Bioscience (TWST) to $135 from $187 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results.
Twist Bioscience price target lowered to $150 from $212 at Guggenheim
Guggenheim lowered the firm’s price target on Twist Bioscience (TWST) to $150 from $212 and keeps a Buy rating on the shares. Twist beat on revenue and gross margins and…
Twist Bioscience price target lowered to $150 from $205 at Canaccord
Canaccord lowered the firm’s price target on Twist Bioscience (TWST) to $150 from $205 and keeps a Buy rating on the shares. The firm is citing its decreased revenue estimates…
Twist Bioscience Earnings Call Transcript: Q4 2026
FY26 revenue rose 22% and Q4 adjusted EBITDA turned positive. FY27 guidance calls for >20% growth, with AI discovery, NGS and capacity expansion as key drivers; planned investment and ramp costs may temper margin expansion.
Twist Bioscience Earnings release: Q4 2026
Twist Bioscience released its Q4 2026 earnings on November 12, 2026, summarizing the period's financial results.
Twist Bioscience Slides: Q4 2026
Twist Bioscience has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on November 12, 2026.
Twist Bioscience Annual report: Q4 2026
Twist Bioscience has published its Q4 2026 annual report on November 12, 2026.
Twist Bioscience sees FY27 revenue $550M-$560M, consensus $548.67M
For the full fiscal year 2027, Twist expects: Total revenue in the range of approximately $550 million to $560 million, growth of approximately 21% year over year at the midpoint.
Twist Bioscience sees Q1 revenue $130M-$132M, consensus $126.42M
For the first quarter of fiscal 2027, Twist expects: Total revenue of approximately $130 million to $132 million, growth of approximately 26% year over year at the midpoint and continued…
Twist Bioscience reports Q4 EPS (32c), consensus (20c)
Reports Q4 revenue $126.6M, consensus $123.63M. “Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quart...
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced financial results and business highlights for ...
Twist Bioscience announces inducement grants under Nasdaq listing rule
As required by the rules of the Nasdaq Stock Market, Twist Bioscience (TWST) announced that a total of 17,681 restricted stock units will be granted to 19 recently hired individuals,…
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value he...
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-foun...
Twist Bioscience down 12% to $125.16 after Hunterbrook report
10:42 EST Twist Bioscience (TWST) down 12% to $125.16 after Hunterbrook report
Twist could repeat its 95% stock collapse, says Hunterbrook CEO
Hunterbrook CEO Nathaniel Horwitz argues in an article for The Bear Cave that Twist Bioscience (TWST) may be overvalued, despite rapid growth and renewed investor enthusiasm tied to its work…
Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Le...
Twist Bioscience announces launch of Twist MRD Express
Twist Bioscience (TWST) launched Twist MRD Express. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research,...
Twist Bioscience Launches MRD Express with Rapid Turnaround Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at s...
Twist Bioscience expands portfolio with Twist Express Screening Antibodies
Twist Bioscience (TWST) expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies. “As AI-guided drug discovery approaches dramatically expa...